Drug Patents owned by Heron Theraps Inc

1. Drug name - CINVANTI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9974793 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof Sep, 2035

(12 years from now)

US9808465 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof Sep, 2035

(12 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof Sep, 2035

(12 years from now)

Drugs and Companies using APREPITANT ingredient

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
130MG/18ML (7.2MG/ML) EMULSION;INTRAVENOUS Prescription

2. Drug name - SUSTOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252305 HERON THERAPS INC Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron Sep, 2024

(1 year, 11 months from now)

US10357570 HERON THERAPS INC Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron Sep, 2024

(1 year, 11 months from now)

US9913910 HERON THERAPS INC Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron Sep, 2024

(1 year, 11 months from now)

US8252304 HERON THERAPS INC Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron Sep, 2024

(1 year, 11 months from now)

US8715710 HERON THERAPS INC Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron Sep, 2024

(1 year, 11 months from now)

Drugs and Companies using GRANISETRON ingredient

Treatment: Treatment or prevention of nausea and vomiting; Prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy

Dosage: INJECTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
10MG/0.4ML (10MG/0.4ML) INJECTION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

3. Drug name - ZYNRELEF KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253504 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent Mar, 2034

(11 years from now)

US9592227 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent Mar, 2034

(11 years from now)

US9913909 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent Mar, 2034

(11 years from now)

US10398686 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent Mar, 2034

(11 years from now)

US9744163 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent Mar, 2034

(11 years from now)

US11083797 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US9694079 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US11083730 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US10980886 HERON THERAPS INC Compositions of a polyorthoester and an organic acid excipient Apr, 2035

(12 years from now)

US10632199 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US10898575 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US9801945 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US10213510 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US10098957 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient

Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation

Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR

More Information on Dosage
Strength Dosage Availability
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription

availability in other generic markets.

Click on the highlighted region to filter.